The calcium-sensing receptor suppresses epithelial-to-mesenchymal transition and stem cell-like phenotype in the colon

Aggarwal et al.
The calcium-sensing receptor suppresses epithelial-to-mesenchymal transition and stem cell-like phenotype in the colon

Abhishek Aggarwal¹, Maximilian Prinz-Wohlgenannt¹, Charlotte Gröschel¹, Samawansa Tennakoon¹, Anastasia Meshcheryakova¹, Wenhan Chang², Edward M Brown³, Diana Mechtcheriakova¹ and Enikő Kállay¹*

Abstract

Background: The calcium sensing receptor (CaSR), a calcium-binding G protein-coupled receptor is expressed also in tissues not directly involved in calcium homeostasis like the colon. We have previously reported that CaSR expression is down-regulated in colorectal cancer (CRC) and that loss of CaSR provides growth advantage to transformed cells. However, detailed mechanisms underlying these processes are largely unknown.

Methods and results: In a cohort of 111 CRC patients, we found significant inverse correlation between CaSR expression and markers of epithelial-to-mesenchymal transition (EMT), a process involved in tumor development in CRC. The colon of CaSR/PTH double-knockout, as well as the intestine-specific CaSR knockout mice showed significantly increased expression of markers involved in the EMT process. In vitro, stable expression of the CaSR (HT29CaSR) gave a more epithelial-like morphology to HT29 colon cancer cells with increased levels of E-Cadherin compared with control cells (HT29EMP). The HT29CaSR cells had reduced invasive potential, which was attributed to the inhibition of the Wnt/β-catenin pathway as measured by a decrease in nuclear translocation of β-catenin and transcriptional regulation of genes like GSK-3β and Cyclin D1. Expression of a spectrum of different mesenchymal markers was significantly down-regulated in HT29 CaSR cells. The CaSR was able to block upregulation of mesenchymal markers even in an EMT-inducing environment. Moreover, overexpression of the CaSR led to down-regulation of stem cell-like phenotype.

Conclusions: The results from this study demonstrate that the CaSR inhibits epithelial-to-mesenchymal transition and the acquisition of a stem cell-like phenotype in the colon of mice lacking the CaSR as well as colorectal cancer cells, identifying the CaSR as a key molecule in preventing tumor progression. Our results support the rationale to develop new strategies either preventing CaSR loss or reversing its silencing.

Keywords: Calcium-sensing receptor, Tumor suppressor, Colon, Inflammation, Cancer, EMT, Cancer stem cell, Calcimimetic

Background

Colorectal cancer (CRC) is the second most frequently diagnosed malignant tumor in females, third most in males, and ranks second in cancer related deaths worldwide [1,2]. Chronic inflammation is one of the major risk factors to develop colorectal tumors [3]. Patients with inflammatory bowel disease have an increased risk to develop cancer [4,5]. Although progress in therapy to manage locally advanced or metastatic CRC patients have evolved, the 5-year survival rate continues to be poor (www.cancer.org).

Epithelial-to-Mesenchymal Transition (EMT) is a reversible, cellular trans-differentiation process by virtue of which epithelial cells acquire mesenchymal traits of plasticity, mobility, stem cell-like and invasive properties [6]. The EMT process, which is normally active during embryogenesis and wound healing (Type 1 EMT), can be activated also during tissue regeneration and fibrosis.
upon initiation by inflammation (Type 2 EMT) [7]. Type 3 EMT occurs during tumor progression when cancer cells exploit this mechanism to gain invasive and metastatic potential [7,8]. The reversal of this process, called Mesenchymal-to-Epithelial Transition (MET), is implicated in later stages of metastasis by which metastatic cancer cells reacquire epithelial characteristics in order to form secondary tumors [9].

Activation of the EMT program orchestrates complex transformations in cellular architecture and behavior. A spectrum of EMT regulators, majority of which belong to the zinc-finger family of transcription factors (including, but not restricted to Snai1 (Snail), Snai2 (Slug), Twist, and Zeb) can bind to the promoter of E-Cadherin and repress its transcription [6,10]. Downregulation of E-Cadherin results in loss of the epithelial phenotype (by deregulated inter-cellular junction complexes), accompanied by the induction of genes specific for mesenchymal phenotype (e.g. αSMA, FSP1, FOXC2 and Vimentin). Furthermore, reduction of E-Cadherin-dependent sequestering of cytoplasmic β-catenin results in free β-catenin that is able to translocate to the nucleus and activate the Wnt/β-catenin signaling pathway [11]. These cells also undergo a 'cadherin-switch' leading to a shift from E-Cadherin to N-Cadherin expression, which is operated by the aforementioned epithelial transcriptional repressors [10,12].

In solid tumors, including CRC, recent reports have shown that a small sub-population of cells, within the heterogeneous tumor, acquires features of stem cells [13,14]. These cancer stem cells have the ability of self-renewal and usually increase in number following conventional therapy as these treatments target only the rapidly dividing cells.

The calcium-sensing receptor (CaSR) is a G protein-coupled receptor that regulates systemic calcium homeostasis. In the colon, the CaSR has been shown to play important roles in nutrient sensing and fluid secretion/absorption [15]. CaSR expression is significantly reduced in colorectal tumors [16,17]. Since the chemopreventive properties of Ca2+ are partially mediated by the CaSR [18,19], these effects may be limited in colonic tumors lacking the CaSR. Indeed, the colons of mice lacking the CaSR exhibit aberrant crypt foci, the earliest identifiable pre-neoplastic lesions [20] as well as enhanced intestinal inflammation [20,21] suggesting that the CaSR is important for maintaining normal colonic epithelium.

In this study we aimed to decipher the mechanisms that contribute to the tumor suppressive functions of the CaSR during colorectal tumorigenesis. We demonstrate that the CaSR suppresses EMT and the stem cell-like phenotype both, in vivo in the colon of mice and in vitro, in colon cancer cells, providing rationale for developing pharmacological agents to modulate CaSR sensitivity in colorectal cancer to prevent tumor progression.

**Results**

**Ablation of CaSR leads to induction of EMT-associated markers in the colon of global CaSR/PTH double-knock out mice**

We investigated the consequences of CaSR knockdown on markers of EMT in the colon of two murine models of CaSR gene knockdown.

In the first model, global ablation of exon-5 of the CaSR on a PTH-null background (CaSR WT/−/PTH −/−, DKO) led to a significant upregulation in mRNA expression of the mesenchymal markers αSma, Fsp1, Snai2, Twist2, Vimentin and Zeb1 in the colon compared with control mice (CaSR WT/−/PTH +/−) (Figure 1). Expression of the pluripotency markers, Nanog and Stella, was also significantly elevated in the colon of DKO mice compared with controls (Figure 1).

**Ablation of CaSR leads to induction of EMT-associated markers in the colon of intestine-specific CaSR knock out mice**

We further evaluated protein expression of EMT markers in colon of mice lacking exon-7 of the CaSR specifically in the intestinal epithelium under the control of the Villin promoter (CaSRint-KO). Colonocytes lacking CaSR in the intestinal epithelia showed a clear upregulation in expression of N-Cadherin (in the epithelial cells of the crypt) and of αSma and Vimentin (in the stromal region) compared with wild-type mice (CaSRWT, Figure 2). Although N-Cadherin expression was upregulated in CaSRint-KO mice, expression of E-Cadherin was unaltered compared with CaSRWT mice (data not shown). Interestingly, we also saw populations of Snai1 and Snai2 expressing cells limited to the stroma only in the CaSRint-KO mice (Figure 2).

**Overexpression of the CaSR enhances the epithelial phenotype of HT29 colon cancer cells**

Although of epithelial origin, HT29 colon cancer cells grow as spindle-shaped, elongated cells that contact neighboring cells only focally when cultured in their standard growth conditions. While HT29EMP cells retained this mesenchymal-like phenotype, stable transfection with the CaSR promoted a morphological change in these cells to a more cobblestone-like, well adherent phenotype that displayed complete cell-cell adhesion with the cells growing in densely packed colonies (Figure 3A). Furthermore, mRNA expression of the epithelial marker, E-Cadherin was significantly upregulated in HT29CaSR compared with HT29EMP cells (Figure 3B).

**Overexpression of the CaSR impairs migration and invasion of colon cancer cells**

Since tumor cell spheroids are considered more representative of in vivo conditions, we evaluated the role of the CaSR in regulating migration and invasion of CRC
cells in a 3D spheroid cell invasion assay. After spheroid formation for 7 days, the migration and invasion potential of 3D cellular aggregates into the surrounding matrix was evaluated.

HT29CaSR cells had significantly lower invasive index (area of the invading spheroids) compared with cells that were transfected with the empty vector (Figure 3C). To distinguish between effects on migration and invasion, we additionally quantified the number of daughter spheroids that had migrated away from the primary spheroid. Overexpression of the CaSR significantly reduced the number of invading daughter spheroids compared with control cells (Figure 3D).

Overexpression of the CaSR attenuates nuclear translocation of β-catenin in HT29 colon cancer cells

Previous studies have shown that loss of CaSR promotes migration and invasion of CRC cells by regulating the Wnt/β-catenin pathway [20,22,23]. Since ectopic CaSR enhanced the epithelial phenotype whilst inhibiting the invasiveness of HT29 cells, we examined whether restoration of CaSR expression was indeed able to regulate Wnt/β-catenin activity. We measured β-catenin expression in protein lysates from nuclear and cytosolic fractions of HT29EMP and HT29CaSR cells. Cells overexpressing the CaSR had a marked decrease in the amount of nuclear β-catenin (Figure 4A). The ratio of nuclear to cytosolic β-catenin in HT29CaSR cells was significantly decreased by 43% compared with HT29EMP cells (Figure 4B). Concomitantly we found significantly higher GSK-3β mRNA expression in these cells (Figure 4C).

We showed that overexpression of CaSR increased expression of the differentiation markers, CDX2 and Villin (Figure 4D and E), and downregulated expression of the proliferation marker, Cyclin D1 (Figure 4F).

CaSR suppresses EMT in HT29 colon cancer cells

NPS R-568, a positive allosteric modulator of the CaSR increases sensitivity of the receptor to its ligands, including Ca2+ [24]. Interestingly, treatment with NPS R-568 upregulated the endogenous expression of the CaSR in HT29EMP cells (Figure 5A). Both, the ectopic (HT29CaSR) and the endogenous CaSR (HT29EMP treated with NPS R-568) were able to induce expression of E-Cadherin (distinctively in the cell membrane) (Figure 5B) and down-regulate the expression of the mesenchymal markers such as αSMA and Vimentin (Figure 5C and D).
We next evaluated whether the presence of the CaSR would further prevent induction of EMT in HT29 cells. Stably transfected HT29 cells were treated with a commercially available EMT inducing cocktail. Upon treatment, HT29 EMP cells were robustly induced towards the mesenchymal phenotype as assessed by significant upregulation in mRNA expression of the mesenchymal markers αSMA, FOXC2, SNAI1, TWIST2, Vimentin and Zeb1 (Figure 6). Interestingly, in HT29CaSR cells, ectopic reintroduction of the CaSR was able to block EMT induction in these cells (Figure 6).

These results were confirmed at protein level by immunofluorescence staining (Figure 7). Treatment with the EMT promoting cocktail induced protein expression markers αSMA, FOXC2, SNAI1, TWIST2, Vimentin and Zeb1 (Figure 6). Interestingly, in HT29CaSR cells, ectopic reintroduction of the CaSR was able to block EMT induction in these cells (Figure 6).

Figure 2 Effect of intestine-specific CaSR knock-down in vivo on EMT-associated genes in the colon. Colons sampled from CaSR<sup>−/−</sup> (CaSR<sup>int-KO</sup>) and CaSR<sup>+/+</sup> (CaSR<sup>WT</sup>) mice were investigated for protein expression of mesenchymal markers αSma, N-cad, Snai1, Snai2 and Vimentin. Representative images in black and white for the markers are shown in addition to the merged images (red or white channels for the indicated markers and blue for DAPI). n = 5 animals/group. Scale bar: 50 μm.
of mesenchymal markers, αSMA and Vimentin only in HT29<sup>EMP</sup> cells, which was blocked by ectopic expression of CaSR. In HT29<sup>CaSR</sup> cells, the upregulated E-Cadherin expression was downregulated upon treatment with the EMT promoting cocktail but remained higher than in HT29<sup>EMP</sup> cells (Figure 7).

**CaSR suppresses stem cell-like phenotype in HT29 colon cancer cells**

Since HT29 cells display expression of pluripotency-related genes, we evaluated whether expression of the CaSR could decrease the cancer stem cell-like properties of these cells. We cultured the stably transfected HT29<sup>CaSR</sup> and HT29<sup>EMP</sup> cells in a commercially available stem cell medium, and assessed expression of the pluripotency related genes Nanog, Oct3/4, Stella and FOXC2. mRNA expression levels of these markers was significantly lower in HT29<sup>CaSR</sup> cells compared with HT29<sup>EMP</sup> cells (Figure 8A).

Increasing CaSR levels, either by transfection (HT29<sup>CaSR</sup>) or by treatment with NPS R-568 reduced the stem-like phenotype in these cells by downregulating expression of pluripotency associated genes, SOX2, Nanog, Oct4, and the colon cancer stem cell marker, CD44 (Figure 8B).

Functionally, cancer stem cells are defined by their ability of self-renewal and form spheres *in vitro* under extreme limited dilutions [25]. Therefore, we examined whether the presence of the CaSR could block the ability of the cells to form colonospheres (*in vitro* spheroidal aggregates). When performing a limiting-dilution assay in hanging drop cultures, we found a significant difference in the spheroid forming ability between HT29<sup>CaSR</sup> and HT29<sup>EMP</sup> cells. While HT29<sup>EMP</sup> cells needed 5 cells/drop to form spheroids in 50% of the drops (Figure 8C, open squares), HT29<sup>CaSR</sup> cells required 8-fold more cells (40 cells/drop) to form spheroids in 50% of drops (Figure 8C, filled circles). Performing the Extreme Limiting Dilution Analysis (ELDA) revealed a 4-fold lower frequency (*p < 0.001*) in forming spheroids in HT29<sup>CaSR</sup> cells compared with HT29<sup>EMP</sup> cells (Figure 8A).
frequency: 1/60) compared with the vector-transfected control HT29 EMP cells (frequency: 1/15) indicating that the enrichment in these stem cell-like cells was inversely proportional to CaSR expression.

CaSR expression positively correlates with the epithelial marker E-Cadherin, and negatively with markers of the mesenchymal lineage in human CRC samples
We evaluated in silico the correlation between CaSR expression and a signature of EMT markers using data available from the GEO database. This study by Ryan and colleagues [26] deposited microarray data from 111 tumor and adjacent mucosa samples from CRC patient samples.
Correlation analysis revealed a significant, negative correlation between the CaSR and markers of the mesenchymal lineage (N-Cadherin, Twist1, αSMA, Vimentin, β-Catenin, Snai2), whereas expression of the epithelial marker, E-Cadherin correlated positively with CaSR expression (Table 1).

Discussion
The calcium-sensing receptor (CaSR) has gained importance outside its physiological role as a regulator of calcium homeostasis. Several model systems have provided convincing evidence for the role of the CaSR as a tumor suppressor in the colon [18]. However, evidence describing the molecular mechanisms causing the tumor suppressive functions of the colonic CaSR is limited. In this study we demonstrate a causal relation between the CaSR and regulation of Epithelial-to-Mesenchymal Transition (EMT) as well as acquisition of the mesenchymal phenotype and prevents acquisition of the stem cell-like phenotype. All preliminary experiments were conducted in two colon cancer cell lines: HT29 and Caco2-15, stably overexpressing the CaSR (or the empty control vector). The results obtained from both cell lines were comparable and therefore, we focused on the HT29 cell line, which has negligible endogenous expression of CaSR.

In light of recent advances in developmental biology and biology of cancer, EMT has emerged as a critical process in the pathophysiology of inflammation and cancer [7,27,28]. Chronic inflammation in patients with inflammatory bowel disease (IBD) increases the risk of

Figure 4 Ectopic CaSR prevents nuclear β-catenin translocation in HT29 colon cancer cells. (A) HT29 cells overexpressing the CaSR (HT29CaSR) show reduced β-catenin nuclear translocation as assessed by western blot and (B) by quantification of β-catenin signal normalized to house-keeping genes (Lamin C: nuclear fraction and α-Tubulin: cytosolic fraction). (C-F) HT29CaSR cells show increased mRNA expression of GSK-3β, of the differentiation markers CDX2 and Villin, and reduced levels of the proliferation marker Cyclin D1 compared with HT29 EMP cells. Data represent mean ± SEM of three independent experiments. Statistical significance was calculated using t test. *p < 0.05, **p < 0.01, ***p < 0.001.
CRC development. Chemically induced, as well as genetically engineered mouse models of IBD have an increased susceptibility to develop colorectal tumors [28]. In this study, we have evaluated the expression of EMT associated markers in the colon of the exon 5-less global CaSR/PTH double knockout mouse as well as in the colon of the exon 7-less intestine-specific CaSR knockout mice. The colons of both, the global CaSR/PTH double knock out and the intestine-specific CaSR knockout mice show signs of inflammation [20,21] and immune cell activation [21] as seen also in patients with IBD [28]. We demonstrate for the first time in vivo, that in both models expression of EMT-associated mesenchymal markers were significantly upregulated in the colon of mice lacking the CaSR, suggesting a critical role of the receptor in suppressing EMT.

Type 2 EMT is associated with tissue regeneration and fibrosis after inflammation-associated injury. As a result, macrophages and activated fibroblasts (myofibroblasts) expressing high levels of mesenchymal markers like FSP1 and αSMA accumulate [7,29]. In some cases, epithelial cells retain a normal epithelial morphology, expressing epithelial markers like E-Cadherin but expression of mesenchymal markers is also induced [29] and cells develop into an intermediate EMT phenotype. The extent of the EMT process depends on the intensity and length of the inflammatory process as has been reported in organs like kidney, lung and intestine [7]. Eventually, these cells acquire mesenchymal characteristics, lose cell-cell contact, migrate out of the epithelial layer and enter the interstitium, where they forego their epithelial phenotype and attain a mesenchymal phenotype [30]. Therefore it is not surprising, that we observe enrichment in populations of stromal cells staining positive for expression of mesenchymal markers in the colon of the CaSr\textsuperscript{int-KO} mice. In the colon of these mice, the cadherin-switch leads to a significant upregulation of N-Cadherin expression without significant alterations in E-Cadherin levels. Such
cadherin switch has been previously reported in other cancers [12,31].

The enhanced inflammatory/immune cell microenvironment can eventually lead to cancer through the inflammation-dysplasia-carcinoma sequence. Extracellular calcium is known to have tumor preventing effects in colorectal cancer [32] and these effects are mediated by the CaSR [18,22,23]. CaSR-null cells, which represent a subpopulation of colon cancer cells, indeed show an enhanced malignant phenotype with increased migration potential and enhanced expression of EMT markers [33].

Several colon cancer cell lines of epithelial origin, including the HT29 cells used in this study, are reprogrammed to acquire an EMT-like phenotype (mesenchymal-like morphology, loss of cell-cell adherence and a highly metastatic and invasive phenotype). These cell lines have low endogenous CaSR expression compared with more differentiated colon cancer cells having a more epithelial phenotype (e.g. Caco-2 cells) [34]. In normally functioning colon cells, β-catenin (a member of the canonical Wnt pathway) binds to E-cadherin and is involved in cell-cell adhesion. Free cytosolic β-catenin is marked for degradation in the proteasome by the APC/Axin/GSK-3β destruction complex. However, when the Wnt pathway is activated, cytosolic β-catenin is translocated to the nucleus where it binds to the Transcription Factor (Tcf)-4 and regulates transcription of genes involved in proliferation, differentiation and apoptosis [11,35-39]. Active Wnt signaling can prevent GSK-3β induced degradation of Snail, and thereby promote EMT [40].

In the present study we show that reintroduction of the CaSR induced a transformation in the morphological architecture of HT29 cells from a more spindle-like, fibroblast-like phenotype to a well adherent, epithelial-like phenotype. These cells also showed reduced cellular invasiveness and migration, two critical steps for initiation of metastasis. Furthermore, HT29 cells overexpressing the CaSR had increased GSK-3β and E-Cadherin expression, in parallel with reduced nuclear β-catenin and Cyclin D1 levels. These data support previous findings that the CaSR suppresses the malignant behavior of CRC cells by modulating the Wnt signaling pathway [20], which is often deregulated in CRC. Rey and colleagues have previously shown the CaSR-dependent regulation of Wnt/β-catenin

Figure 6 Ectopic CaSR prevents induction of mRNA expression of EMT markers in HT29 colon cancer cells. HT29CaSR cells (grey bars) show downregulation in mRNA expression of mesenchymal markers αSMA, FOXC2, SNAI1, TWIST2, Vimentin and Zeb1 compared with HT29EMP cells (white bars). Treatment with EMT promoting cocktail, further induced mesenchymal transition in HT29EMP cells (white striped bars), which was blocked by ectopic expression of CaSR (HT29CaSR, grey striped bars). Data represent mean ± SEM of three independent experiments. Statistical significance was determined by ANOVA followed by Tukey’s post-test. Asterisks above bars indicate all significant changes. *p < 0.05, **p < 0.01, ***p < 0.001.
pathway in a normal colonic epithelial cell line with a functional APC gene [41]. It is interesting that although HT29 cells harbor a mutation in the APC gene, overexpression of the CaSR is able to counteract defective β-catenin activity in these cells.

Singh and colleagues have recently observed an EMT-driven, highly malignant phenotype in CaSR-null cells [33]. However, it remained elusive to what extent the CaSR is able to regulate/interfere in the EMT process. By treating stably transfected HT29 cells with an EMT inducing supplement, we are the first to report that the CaSR is effective in reversing the EMT phenotype and that the presence of the CaSR effectively blocks the transition from an epithelial to a mesenchymal state even under EMT promoting conditions. We further show that treatment with the calcimimetic, NPS R-568 previously described as a pharmacochaperone of the CaSR [42], was able to induce endogenous CaSR expression. Both, ectopic overexpression and enhancement of endogenous CaSR expression and activity (treatment with NPS R-568) is able to reverse the EMT phenotype by upregulating expression of E-Cadherin, which becomes localized to the cell membrane, and by downregulating expression of EMT-associated mesenchymal markers.

In several cancers, acquisition of EMT characteristics leads to a parallel increase in pluripotency-associated markers like Nanog, Stella and Oct3/4 [43,44]. In solid tumors (like the colon), these subpopulations of cells, which express cell surface markers like CD44, are termed cancer stem-like cells. These cancer stem cells, although controversial, have attained a lot of research interest recently for their contribution to recurrence/re-lapse of chemoresistant tumors [45]. HT29 cells express cancer stem cell markers abundantly. Since reintroduction of the CaSR induces a more differentiated phenotype, we predicted a reduction in their stem-like phenotype as well. Culturing colonospheres (in vitro spheroids) of stably transfected HT29EMP and HT29CaSR cells in chemically defined media supporting growth of stem cells [46], we were able to show that the CaSR was not only able to downregulate expression of markers associated with stemness, but was also able to reduce the ability to form tumor-associated spheroids.

**Conclusions**

Our data demonstrates that reintroduction of the CaSR prevents the development of a highly malignant, stem cell-like phenotype in colon cancer cells. The mechanisms...
involved in this process advance our understanding of the molecular changes in colon cancer cells accompanying the loss of CaSR. We show that the CaSR is necessary for calcium-mediated growth control in the colon. These data support the rationale to develop pharmaceutical agents to restore expression and function of colonic CaSR during colonic inflammation and cancer.

Methods

CaSR/PTH double-knockout mouse (CaSR<sup>−/−</sup>/PTH<sup>−/−</sup>)

Mice heterozygous for CaSR<sup>ΔExon5</sup> and PTH were bred to generate CaSR<sup>+/−</sup>/PTH<sup>−/−</sup> and CaSR<sup>−/−</sup>/PTH<sup>−/−</sup> mice as previously described [47]. All mice were maintained under standard conditions as approved by the Institutional Animal Care and Use Committee at Harvard Medical School. Age- and sex-matched animals (n = 9/genotype) were sacrificed; colons were washed in ice-cold PBS and stored in RNAlater (Life Technologies, Austria). For mRNA analysis, 1–2 cm of colonic tissue, 0.5 cm distal from cecum was used.

Intestine specific CaSR knockout mouse (CaSR<sub>int-KO</sub>)

CaSR<sub>Box/Box</sub> mice [48] were bred with mice genetically engineered to express Cre-recombinase under the control of the villin 1 promoter to produce <sup>Cre</sup>/CaSR<sub>Box/Box</sub> and CaSR<sub>Box/Box</sub> mice, as previously described [41]. All mice

---

Figure 8 Overexpression of CaSR blocks acquisition of stem cell-like characteristics. HT29 cells overexpressing the CaSR (HT29<sup>CaSR</sup>) or empty transfected cells (HT29<sup>EMP</sup>) were grown in stem cell media. (A) Ectopic expression of CaSR blocked acquisition of the pluripotency markers Nanog, Oct3/4, Stella, and FOXC2. (B) Treatment with NPS R-568 or overexpression of CaSR diminished expression of pluripotency-associated markers Sox2, Nanog, Oct4 and CD44. (C) Extreme limiting dilution assay revealed a significantly lower sphere forming ability of stem-like cells in HT29<sup>CaSR</sup> cells. Data represent mean ± SEM of 3-5 independent experiments. Scale bar: 50 μm. Statistical significance was calculated using t test. *p < 0.05, **p < 0.01.
were maintained under standard conditions as approved by the Animal Care Subcommittee at San Francisco Department of Veterans Affairs Medical Center. Age- and sex-matched animals (n = 5/genotype) were sacrificed, whole colons were washed in ice cold PBS, fixed and embedded in paraffin until further analysis.

Cell culture, cloning and stable transfection

The human colon cancer cell line HT29 was obtained from American Type Culture Collection (ATCC, USA) and was routinely maintained in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS, 1.8 mM Ca²⁺, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (all from Life Technologies) in a 5% CO₂/humidified air incubator maintained at 37°C. Cells were periodically tested for mycoplasma contamination and authenticated by STR DNA profiling (DNA Diagnostic Center, UK).

HT29 cells were transfected with pcDNA3.1/Zeo(+) (EMP) or an expression vector encoding the full length CaSR cDNA (constructs kindly provided by Prof. Romuald Mentaverri, University of Picardie Jules Verne, France) using Lipofectamine LTX reagent (Life Technologies) as previously described [18]. Stable transfectants were selected by culturing the cells in the presence of Zeocin (150 μg/ml) for over 6 months.

Invasion assay

In vitro cellular invasion was determined using the Cultrex® 3D Spheroid Cell Invasion Assay (Trevigen, USA) according to the manufacturer’s instructions. Briefly, cells were seeded at a density of 3000 cells/cm² (in triplicates) in 96-well spheroid forming plates along with an extracellular matrix to drive aggregation of spheroids. After 72 hours, the spheroids were allowed to invade into a matrix composed of basement membrane proteins. Cellular invasion was visualized with a bright field microscope and quantified using Adobe Illustrator (Adobe Systems, USA) to calculate the area of the invading spheroids (invasive index) and the number of invading daughter spheroids. The assay was performed in three independent experiments.

Nuclear and cytosolic protein extraction and western blot analysis

In order to retrieve nuclear and cytosolic protein fractions, cells were cultured to 60-70% confluency, collected in ice-cold PBS and centrifuged. The pellet was first resuspended for 15 minutes in a hypotonic buffer (10 mM Hepes pH 7.5, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, DTT, PMSF, protease and phosphatase inhibitors and 10% NP40 (all from Sigma Aldrich, Germany) and centrifuged to obtain the soluble cytosolic fraction in the supernatant. Next, the pellet was resuspended in a high salt buffer (20 mM Hepes pH 7.5, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, DTT, PMSF, protease and phosphatase inhibitors) for 15 minutes to obtain the soluble nuclear fraction by centrifugation. Protein concentration was measured using Protein Assay Dye (Bio-Rad, USA).

Equal amounts of protein lysate were separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. Membranes were blocked in 5% milk (in 10 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween-20 (TBST)) for 1 h at room temperature (rt) and subsequently incubated with the primary antibodies (in TBST) for 1 h at rt. After washing, the membrane was incubated with respective secondary antibody for 1 h at rt. The membrane was subjected to ECL reagent (Bio-Rad), and protein bands were detected using a digital imaging system (VersaDoc) and quantified using Image Lab software (Bio-Rad).

Primary antibodies used were β-Catenin (1:5000, Abcam, UK), α-Tubulin (1:10000, Sigma Aldrich), Lamin C (1:1000, Santa Cruz Biotechnology Inc, USA). Secondary antibodies used were horseradish-peroxidase-coupled anti-mouse (1:5000, Jackson ImmunoResearch, UK), anti-rabbit (1:10000, Jackson ImmunoResearch) and anti-goat (1:20000, AbD Serotec, UK) IgG.

| Table 1 Correlation matrix for expression of CaSR and EMT markers in human colorectal cancer samples |
|-------------------------------------------|--------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| CaSR                                     | N-Cadherin                  | E-Cadherin     | TWIST1         | αSMA           | Vimentin       | β-Catenin      | FSP1           | SLUG           |
| CaSR                                     | 1.000                       | - .267         | .314           | - .212         | - .259         | - .227         | - .248         | - .152         | - .397         |
| N-Cadherin                               | - .267**                    | 1.000          | - .157         | .015           | .178           | .136           | .100           | .209           | .118           |
| E-Cadherin                               | .314**                      | - .157         | 1.000          | - .297**       | - .230         | - .362**       | - .157         | - .322**       | - .322**       |
| TWIST1                                   | - .212*                     | .015           | - .297**       | 1.000          | .193*          | .259*          | .101           | .417**         | .417**         |
| αSMA                                     | - .259**                    | .178           | - .230         | .193*          | 1.000          | .657**         | - .054         | .559**         | .358**         |
| Vimentin                                 | - .227**                    | .136           | - .362**       | .259*          | .657**         | 1.000          | .077           | .432**         | .529**         |
| β-Catenin                                | - .248**                    | .100           | - .157         | .101           | .054           | .077           | 1.000          | - .057         | .256**         |
| FSP1                                     | - .152                      | .209           | - .322**       | .417**         | .559*          | .432**         | - .057         | 1.000          | .408**         |
| SLUG                                     | - .397**                    | .118           | - .322**       | .417**         | .358**         | .529*          | .256**         | .408**         | 1.000          |

Correlation analysis was performed across 111 human colorectal cancer samples of tumor and adjacent non-tumor mucosa. Spearman correlation coefficient and corresponding p value is shown. **p< 0.01, *p< 0.05.
**Induction of EMT**
Stably transfected cells were treated with a commercially available EMT-inducing cocktail for HT29 cells according to the manufacturer’s instructions (R&D Systems, USA) [49]. Cells were cultured in DMEM media containing 5% FCS and 1.8 mM Ca\(^{2+}\) in the presence or absence of 1X EMT inducing supplement for 6 days and data analyzed for mRNA/protein expression.

**Induction of stem cell-like phenotype**
Stably transfected cells were cultured in the commercially available Essential 8 stem-cell media [46] according to the manufacturer’s instructions (Life Technologies). Cells were cultured for 6 days and analyzed for mRNA/protein expression and colonosphere-forming ability. For protein expression studies, stably transfected cells were also treated with 1 \(\mu\)M NPS R-568 (in DMSO). Vehicle-treated cells were used as controls.

For the colonosphere-forming assay we modified the extreme limiting dilution analysis (ELDA) by Yu et al. [50] originally described by Hu and Smyth [51]. Cells were trypsinized to obtain single-cell suspension and were then seeded at the concentrations of 100, 40, 20, 10, 5, and 1 cell(s) per 50 \(\mu\)l Essential 8 media (6 replicates for each dilution/run) as hanging drop cultures. One week post seeding, the percentage of wells positive for formation of colonospheres was determined and plotted against the number of cells seeded per drop. Sphere forming frequency was determined using the ELDA analysis tool at http://bioinf.wehi.edu.au/software/elda.

**RNA isolation, reverse transcription and quantitative RT-PCR**
Total RNA was isolated using Trizol reagent (Life Technologies) according to the manufacturer’s instructions. Integrity of RNA was checked by agarose gel electrophoresis, and RNA was reverse transcribed as previously described [52]. qRT-PCR was performed on the Step One Plus qRT-PCR system using Power SYBR Green master mix (Life Technologies). Where possible, primers were designed to bridge an exon-exon junction to prevent genomic DNA from being amplified. The \(\Delta\Delta\)C\(_{T}\) method was used to calculate fold changes in gene expression, relative to housekeeping genes and normalized to a commercially available total RNA calibrator (Clontech, USA) according to Livak et al. [53].

Human Beta-actin (h\(\beta\)-ACTIN), human Large ribosomal protein (hRPLPO) and/or human Beta-2-microglobulin (h\(\beta\)2M) were used as housekeeping genes for samples of human origin; mouse \(\beta\)-actin and mouse Eukaryotic translation elongation factor 1 beta 2 (m\(\text{Eef1B2}\)) were used as housekeeping genes for mouse colon samples. Primer sequences are shown in Additional file 1: Table S1.

**Immunostaining**
 Cells grown on glass cover slips under experimental conditions as well as paraffin-embedded 5-\(\mu\)m tissue sections were stained as previously described [17]. Samples were incubated with primary antibodies for 1 h at rt. Isotype-specific IgG antibodies were used as negative controls. Samples were subsequently incubated with corresponding secondary antibodies for a further 1 h at rt. Nuclei were stained with DAPI (1:3000, Roche, Switzerland) and images acquired with the TissueFAXS system (TissueGnostics, Austria).

Primary antibodies used were, anti-E-Cadherin (1:200), anti-Snai1 (1:100), anti-Snai2 (1:200) and anti-Vimentin (1:100), (EMT Antibody Kit, Cell Signaling Technologies, Austria) and anti-Sox2, anti-Nanog, anti-Oct4 (all 1:400, StemLight™ Pluripotency Transcription Factor Antibody Kit, Cell Signaling Technologies). Anti-CaSR (1:200) and anti-CD44 (1:100) antibodies were purchased from Abcam and the anti-aSMA (1:100) was purchased from Sigma Aldrich. Secondary antibodies used were: Alexa Fluor-647 goat-anti-mouse (1:1,000, Life Technologies) or Dylight labeled-549 goat-anti-rabbit antibody (1:500, Vector Laboratories).

**Acquisition and processing of public microarray data**
Raw microarray data was obtained from the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) database. The dataset GSE44861 deposited by Ryan and colleagues contained log2 transformed expression data from 111 tumor and adjacent non-tumor samples from CRC cancer patients [26] and was used to compute the correlation between the CaSR and EMT markers studied.

**Statistical analysis**
All assays were performed in at least three independent experiments. For comparison between 2 groups, t-test was used. For group comparisons, Analysis of Variance (ANOVA) was performed followed by Tukey’s post-test. Non-normally distributed data were log-transformed to achieve normal distribution. Correlation coefficients were calculated using the nonparametric Spearman’s correlation. P values <0.05 were considered statistically significant. SPSS (IBM, USA) was used to perform all statistical calculations and graphs were plotted using GraphPad Prism (GraphPad Software Inc., USA).

**Additional file**

**Additional file 1: Table S1.** Details of primers used in the study.

**Abbreviations**
SMA: alpha smooth muscle actin; ANOVA: Analysis of variance; CaSR: Calcium-sensing receptor; CDX2: Caudal type homeobox 2; CRC: Colorectal cancer; ELDA: extreme limiting dilution analysis; EMT: Epithelial-to-mesenchymal transition; FOXC2: Forkhead box protein C2;
FSP: Fibroblast specific protein; IBD: Inflammatory bowel disease; MET: Mesenchymal-to-epithelial transition; PTH: Parathyroid hormone; Snail: Snai1; Slug: Snai2; TCF4: Transcription factor 4; ZEB: Zinc finger E-box binding; S-FU: 5-fluouracil.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Conception and design – AA, EK. Development of methodology – AA, MPW, CG, ST, AM, WC, EMB. Acquisition of data – AA, MPW. Analysis and interpretation of data – AA, MPW, BK. Drafting of the manuscript – AA, EK. Study supervision –DM, EK. All authors read and approved the final manuscript.

Acknowledgements
The authors would like to thank Dr. Sabina Baumgartner-Parzer, Dr. Balazs Mentavari for providing the constructs used in the study. The authors would also like to thank the EU Marie Curie ITN (FP7-264663), Vienna Science and Technology Fund (WWTF, LS12-047) and Austrian Science Fund (FWF; http://www.fwf.ac.at/) for providing the constructs used in the study. The authors would also like to thank Dr. Sabina Baumgartner-Parzer, Dr. Balazs Mentavari for providing the constructs used in the study. The authors would also like to thank the EU Marie Curie ITN (FP7-264663), Vienna Science and Technology Fund (WWTF, LS12-047) and Austrian Science Fund (FWF; http://www.fwf.ac.at/) for providing the constructs used in the study. The authors would also like to thank Dr. Sabina Baumgartner-Parzer, Dr. Balazs Mentavari for providing the constructs used in the study. The authors would also like to thank Dr. Sabina Baumgartner-Parzer, Dr. Balazs Mentavari for providing the constructs used in the study. The authors would also like to thank Dr. Sabina Baumgartner-Parzer, Dr. Balazs Mentavari for providing the constructs used in the study.

Author details
1 Department of Pathophysiology and Allergy Research, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. 2 Endocrine Research Unit, Department of Veteran Affairs Medical Center, University of California, San Francisco, CA, USA. 3 Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Boston, MA, USA.

Received: 22 December 2014 Accepted: 3 March 2015
Published online: 18 March 2015

References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–17.
3. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 1997;11:25–38.
4. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138:2101–2109.
5. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. J Clin Invest. 2015;125:37–43.
6. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–186.
7. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1240–8.
8. De Craene B, Benz G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:597–110.
9. Yoo D, Dai C, Peng S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res. 2009;7:2727–37.
10. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–186.
11. Thiry JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:31–41.
12. Clevers H. Wnt-beta-catenin signaling in development and disease. Cell. 2006;127:469–80.
13. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J Cell Sci. 2008;121:727–35.
14. Roy S, Majumdar AP. Cancer stem cells in colorectal cancer: genetic and epigenetic changes. J Stem Cell Res Ther. 2012;Suppl 7(6):10342.
15. Bothkin G. Colon cancer stem cells—from basic to clinical application. Cancer Lett. 2013;338:127–40.
16. Geibel JP, Hebert SC. The functions and roles of the extracellular Ca2+−sensing receptor along the gastrointestinal tract. Annu Rev Physiol. 2009;71:205–17.
17. Sheinin Y, Källay E, Wurba F, Kriwanek S, Peterlik M, Cross HS. Immunocytochemical localization of the extracellular calcium-sensing receptor in normal and malignant human large intestine mucosa. J Histochem Cytochem. 2000;48:595–602.
18. Fethahi IS, Höbauer J, Aggarwal A, Hummel DM, Tennakoon S, Mesteri L, et al. Calcium-sensing receptor silencing in colorectal cancer is associated with promoter hypermethylation and loss of acetylation on histone 3. Int J Cancer. 2014;135:2014–23.
19. Aggarwal A, Prinz-Wohlgemann M, Tennakoon S, Höbauer J, Boudot C, Mentavari R, et al. The calcium-sensing receptor: a promising target for prevention of colorectal cancer. Biochim Biophys Acta. 2015; doi:10.1016/j.bbamcr.2015.02.011.
20. Källay E, Köröf O, Chattoppadhyay N, Brown EM, Bischof MG, Peterlik M, et al. Calcium-dependent c-myc proto-oncogene expression and proliferation of Caco-2 cells: a role for a luminal extracellular calcium-sensing receptor. Biochem Biophys Res Commun. 1997;23280–3.
21. MacLeod RJ. Extracellular calcium-sensing receptor/PTH knockout mice colons have increased Wnt/β-catenin signaling, reduced non-canonical Wnt signaling, and increased susceptibility to azoxymethane-induced aberrant crypt foci. Lab Invest. 2013;93:520–7.
22. Cheng SK, Lightfoot YL, Yang T, Zadeh M, Tang L, Sahay B, et al. Epithelial CaSR deficiency alters intestinal integrity and promotes proinflammatory immune responses. FEBS Lett. 2014;588:158–66.
23. Chakrabarty S, Radjendirane V, Appelman H, Varani J. Extracellular calcium and calcium-sensing receptor function in human colon carcinomas: promotion of E-cadherin expression and suppression of beta-catenin/TCF activation. Cancer Res. 2003;63:71–7.
24. Bhagavathula N, Hanosh AW, Nerusu KC, Appelman H, Chakrabarty S, Varani J. Regulation of E-cadherin and beta-catenin by Ca2+ in colon carcinoma is dependent on calcium-sensing receptor expression and function. Int J Cancer. 2007;121:1455–62.
25. Nemeth E. Allosteric modulators of the extracellular calcium receptor. Drug Discov Today Technol. 2013;10:e277–84.
26. Kaywar SS, Yu Y, Nautyal J, Patel BB, Majumdar AP. The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer. 2010;9:212.
27. Ryan BM, Zanetti KA, Robles AJ, Schetter AJ, Goodman J, Hayes RB, et al. Germline variation in NCF4, an innate immunity gene, is associated with an increased risk of colorectal cancer. Int J Cancer. 2014;134:1399–407.
28. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15:117–34.
29. Tkoczwez SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G187–G197.
30. Okada H, Strutz F, Danoff TM, Kalluri R, Neilson EG. Possible mechanisms of renal fibrosis. Contrib Nephrol. 1996;118:147–54.
31. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol. 1999;147:631–44.
32. Wang JL, Lin YW, Chen HW, Kong X, Xiong H, Shen N, et al. Calcium prevents tumorigenesis in a mouse model of colorectal cancer. PLoS One. 2011;6:e25266.
34. Chantret I, Barbat A, Dussaulx E, Brattain MG, Zweibaum A. Epithelial polarity, villin expression, and enterocyte differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. Cancer Res. 1998;58:1936–42.
35. Gregoireff A, Pinto D, Beeghly H, Destrie O, Kielman M, Clevers H. Expression pattern of Wnt signaling components in the adult intestine. Gastroenterology. 2005;129:626–638.
36. Pinto D, Clevers H. Wnt, stem cells and cancer in the intestine. Biol Cell. 2005;97:185–96.
37. Schepers A, Clevers H. Wnt signaling, stem cells, and cancer of the gastrointestinal tract. Cold Spring Harb Perspect Biol. 2012;4:a007989.
38. van de Wetering M, Sancho E, Vanweij C, de Lauw W, Oving I, Hufstone A, et al. The beta-catenin/TCF-4 complex imposes a strict progenitor phenotype on colorectal cancer cells. Cell. 2002;11:241–50.
39. Van der Flier LG, Saborés-Bellver J, Oving I, Haegeman A, De Palo M, Anti M, et al. The Intestinal Wnt/TCF Signature. Gastroenterology. 2007;132:628–32.
40. Yook JI, Li XY, Ota I, Fearon ER, Weiss SJ. Wnt-dependent regulation of the E-cadherin repressor snail. J Biol Chem. 2005;280:11740–8.
41. Rey O, Chang W, Bixel D, Rosengurt N, Young SH, Rosengurt E. Negative cross-talk between calcium-sensing receptor and β-catenin signaling systems in colonic epithelium. J Biol Chem. 2012;287:1158–67.
42. Huang Y, Breitwieser GE. Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis. J Biol Chem. 2007;282:9517–25.
43. Zhang J, Espinoza LA, Kinders RJ, Lawrence SM, Pfister TD, Zhou M, et al. NANOG modulates stemness in human colorectal cancer. Oncogene. 2013;32:4897–485.
44. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.
45. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Nian L, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One. 2008;3:e2428.
46. Chen G, Gulbranson DR, Hou Z, Bolin JM, Ruotti V, Probasco MD, et al. Chemically defined conditions for human iPSC derivation and culture. Nat Methods. 2011;8:424–9.
47. Quinn SJ, Thomsen AR, Pang JL, Kantham L, Bräuner-Osborne H, Pollak M, et al. Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab. 2013;304:E310–20.
48. Chang W, Tu C, Chen TH, Bixel D, Shoback D. The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Sci Signal. 2008;1:ra1.
49. Tang Y, Herr G, Johnson W, Resnik E, Aho J. Induction and analysis of epithelial to mesenchymal transition. J Vis Exp 2013; 78. doi:10.3791/50478.
50. Yu Y, Kanwar SS, Patel BB, Oh PS, Naughtyl J, Sarkar FH, et al. MicroRNA-21 induced stemness by downregulating transforming growth factor beta receptor 2 (TGFBR2) in colon cancer cells. Carcinogenesis. 2012;33:68–76.
51. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347:10–8.
52. Höbäus J, Hummel DM, Thiem U, Fethneh IS, Aggarwal A, Mullauer L, et al. Increased copy-number and not DNA hypomethylation causes overexpression of the candidate proto-oncogene CYP24A1 in colorectal cancer. Int J Cancer. 2013;133:1380–8.
53. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-(Delta Delta CT) Method. Methods. 2001;25:402–8.